News

K2M has obtained the worldwide exclusive rights for all spinal applications of this material through an agreement with Promethean Surgical Devices in November 2008. In furtherance of K2M’s

For the first quarter of 2009, diluted earnings per share were $0.63, a decrease of 17.4%, compared to $0.76 for the first quarter of 2008. The company reported

Orphan drug designation entitles Antigenics to seven years of market exclusivity for Oncophage in the treatment of glioma patients in the event of market approval for this indication.

Revenues for the first quarter of 2009 were $3.16 million, compared to $2.76 million for the same period in 2008. First quarter 2009 revenues were primarily from Sangamo’s

As part of the amendment, Gen-Probe will acquire 4.9 million shares of newly issued DiagnoCure convertible preferred stock for $5 million, representing a premium of 19.8% over the

Mr Ennis was previously Revlon’s executive vice president, CFO and president of Revlon International. Mr Ennis and Mr Kennedy will both remain on the company’s board of directors.

HRA Pharma’s previous CEO and founder, Andre Ulmann, will assume the role of chairman of the company’s supervisory board. Dr Gainer joined HRA Pharma in 2000 and has

In this role, Mr Wilson will have overall leadership responsibility for the strategy and operations for all of the company’s finance and control functions. He will assume his

Mr Teasdale has been with Smith & Nephew for 20 years and has experience in driving top line growth and expanding margins, the company said. Most recently, he